BSGCT’s Annual Conference in 2019 took place from 19th-21st June in Sheffield. The conference brought together scientists from across the UK and beyond to highlight the latest research and techniques in gene and cell therapy.

Presentation Winners
The Fairbairn Award: Alexander Baker - OR23 Adenovirus serotype 26 uses sialic acid bearing glycans as its primary means of infection
• Best Oral Presentation: Evelyne Demkes - OR19 Immune suppression for xeno-cell transplantation strategies in the porcine animal model
• Best Poster Presentation: Keittisak Suwan - P44 Systemic chemovirotherapy against human glioblastoma using temozolomide and bacteriophage-guided gene therapy
• ESGCT Best Oral Presentation: Robyn Bell - OR16 Gene therapy for thrombotic thrombocytopaenic purpura
• ESGCT Best Poster Presentation: James Grey - P43 Non-viral genetic therapy strategies for the treatment of ataxia telangiectasia
• Best Rapid Poster Presentation: Jason Halliwell - P06 Mechanisms that lead to genetic instability in human pluripotent stem cells

Programme    Photos

 


Annual Conference 2019, Sheffield

Genome editing for gene and cell therapy. Technologies, models and translation.

The 1-day conference on Friday 23rd November 2018 gave attendees an overview about the successes, challenges and areas for future development. This is clearly an area of broad interest and with many applications in the context of gene and cell therapy, and we were thrilled to welcome key national and international speakers.
Thank you for joining us!

Presentation Winners
• Best Oral Presentation: Diogo Mosqueira – OR03 CRISPR/Cas9 genome editing in human pluripotent stem cellcardiomyocytes provides a platform for modeling hypertrophic cardiomyopathy
• Best Poster Presentation: Gaetano Naso – P08 CRISPR/Cas9 genome editing of RDEB mutation hotspot
• Best Rapid Poster Presentation: Bart Nieuwenhuis – P02 Comparison of AAV1 and AAV5 viral vector serotypes and four promoters for viral transduction of the corticospinal tract

Programme

Autumn Conference 2018, London

Lentiviral and other retroviral vectors in 2018: Applications, production and vector design relevant for translation into human

Lentviral and retroviral vectors are at the forefront of advanced therapeutic medicinal product (ATMP) development. The 1-day conference on Friday 27th April 2018 aimed to give the attendee an overview about the successes, challenges and areas for future development. The programme was exciting and key national and international speakers including Claire Booth and Luigi Naldini spoke at the conference. The annual Fairbairn Award gave students and early post-docs the chance to compete for the prestigious Fairbairn Award. The conference closed with a moderated questions and answers session, debating the pros and cons of gene editing versus gene addition-based strategies.
An important aspect of our conference is to give early career gene and cell therapists a chance to become involved. This year we, for the first time, included a session on 1-minute rapid poster presentations. Younger members of the BSGCT community werealso be invited to co-chair sessions and validate submitted abstract; important skills to learn, but also valuable additions to CVs.
Thank you for joining us to make the meeting a success.

Presentation Winners
• The Fairbairn Award: Helena Lund-Palau, Imperial College London – FB02 Lentivirus GM-CSF gene therapy for autoimmune pulmonary alveolar proteinosis
Best Poster Presentation: Michael Hughes, University College London – PO09 AAV9 Intracerebroventricular gene therapy improves lifespan and normalises long-term locomotor behaviour in a mouse model of Niemann-Pick type C1 disease
Best Rapid Poster Presentation: Robyn Bell, Imperial College London – PO12 Large transgene strategies for von Willebrand disease
Rapid Poster Presentation Runner Up: Nora Clarke, Imperial College London – PO18 Validation of a PCR-based assay to quantify lentiviral vector shedding in human body fluids

Programme

Spring Conference 2018, London

BSGCT Annual Conference UK Regenerative Medicine Platform Joint Meeting 2017

It was our great pleasure to welcome delegates to the British Society for Gene and Cell Therapy Annual Conference and UK Regenerative Medicine Platform Joint Meeting which was held at the Royal Welsh Academy of Music and Drama, Cardiff, Wales on Wednesday 19th – Friday 21stApril 2017. The programme was centred around “hot topics” in gene and cell therapy, as well as regenerative medicine with talks delivered by leading national and international experts in the field. Specific aims of the meeting included (a) to provide a forum for discussion, (b) to foster collaborations and (c) to identify common hurdles that slow the development of these advanced therapeutic medicinal product. The programme was of broad appeal to scientists, clinicians, students and members of the public with an interest in the field.
This event took a similar format to our last three-day conference at The Technology and Innovation Centre, Glasgow in 2015 with focus on cutting edge science and clinical translation of gene and cell therapy. We focused on engaging early career researchers, PhD, MSc and BSc students who had the opportunity to get involved in all aspects of the conference and organisation. This included opportunities to review abstracts, chair sessions and participate in oral and poster presentations of their research. It was an opportunity for the BSGCT and UK RMP to showcase the best of our future scientific talent in the field of gene and cell therapy.

Presentation Winners
• Fairbairn Award: Michael Paul-Smith, Imperial College, London
• BSGCT Best Oral Presentation: Rebecca Holley, University of Manchester
• BSGCT Best Poster Presentation: Reema Mohammed, University College London
Best Poster Prize (sponsored by Welsh Blood Service): Natalie Suff, University College London

Programme

Annual Conference 2017, Cardiff

The 13th annual meeting of the British Society for Gene and Cell Therapy (BSGCT) reflected the huge interest currently being generated in use of adeno-associated virus as a therapeutic vector. The purpose of the shorter 1 day meeting was to focus in depth on particular topics that are pertinent to the scientific mission of our society. The local organising committee put together a fabulous programme showcasing aspects of AAV biology, use of AAV as a gene transfer and editing tool, and clinical application. We are particularly grateful to our speakers, international experts in the field, for accepting our invitation.
In addition to keynote lectures, we selected the best abstract submissions for short oral presentations, which were judged on the day for the BSGCT Fairbairn award. As is traditional with BSCGT meetings, we recognise the importance of creating opportunities for the next generation of scientific researchers to present their research.
The society is very grateful for the outstanding support for the meeting from our sponsors and exhibitors. Without this, we would not have been able to create such an exciting programme.

Programme

With thanks to our sponsors and partners

Annual Conference 2016, London

This was a full BSGCT Annual Conference (including a Public Education Day, scientific education session, main 48 hr BSGCT meeting, satellite Gene, Cell and Molecular Therapies for Inherited Metabolic Disease Meeting and for the first time a joint meeting with British Society for Cardiovascular Research (BSCR)). The meeting included an exciting programme to highlight novel developments in this area within the field of gene and cell therapy.
This event took a similar format to our main event at RHUL in 2013 with focus on cutting edge science and clinical translation of gene and cell therapy. We also focussed on engaging Early Career Researchers, PhD, MSc and BSc students who once again had the opportunity to get involved in all aspects of the conference and organisation. This included opportunities to review abstracts, chair sessions and participate in oral and poster presentations of their research. This was an opportunity for the BSGCT to showcase the best of our future scientific talent in the field of gene and cell therapy. We had several prizes to award for high calibre scientific presentations, including the prestigious Fairbairn Award for best oral presentation.

Programme

 

Annual Conference 2015, Glasgow

Following the success of our recent BSGCT conference at RHUL 2013, the BSGCT are delighted that the forthcoming annual conference for 2014 which focused on “Advances in Immunology for Gene and Cell Therapy” and held at The Institute of Child Health (ICH), London was a huge success. Immunology impacts all aspects of our work, whether we are trying to avoid, or stimulate immune responses to improve gene therapy approaches for a broad spectrum of diseases. Therefore, the BSGCT were keen to develop an exciting programme to highlight novel developments in this area within the field of gene and cell therapy. This event took a similar format to our one-day event at ICH in 2012, having a focus on engaging early career researchers, PhD, MSc and BSc students who will again have the opportunity to get involved in all aspects of the conference and organisation. This included opportunities to review abstracts, chair sessions and participate in oral and poster presentations of their research. This was an opportunity for the BSGCT to showcase the best of our future scientific talent in the field of gene and cell therapy. We had several prizes on the day to award for high calibre scientific presentations, including the prestigious Fairbairn award for best oral presentation.
We had an exciting programme with sessions covering “Vector engineering for immune therapies/modulation of immune responses”, “Immunotherapy” and finally “Gene therapy vaccines”.

Programme

Annual Conference 2014, London

At the AGM in March 2012, the Society voted unanimously for a name change to British Society for Gene and Cell Therapy (BSGCT) to reflect the increasing synergy between the field of gene therapy and cell biology, in particular stem cell biology. This aligns BSGCT with the European and American organisations, ESGCT and ASGCT. It also reflects the enthusiasm for change and greater interaction between the gene therapy and stem cell communities: A BSGT-sponsored workshop ‘genetic modification meets stem cell biology’ held at the April 2011 UK National Stem Cell Network meeting attracted far more delegates than any other parallel session in the Network’s history. Equally, our Society’s collaborative conference in Brighton with ESGCT in October 2011 attracted over 700 delegates and was a major international success. We are now building on these successes by assembling an outstanding speaker line-up to mix the best of gene and cell therapy with stem cell biology for the 2013 BSGCT conference (April 17-19, Royal Holloway, London).

Programme

Annual Conference 2013, Royal Holloway